Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. covers events occurring on May 10, 2018, and May 12, 2018, with the report filed on May 15, 2018. The document details the results of the Company's 2018 Annual Meeting of Stockholders and a subsequent Board of Directors action regarding a new director appointment.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Corporate Actions
Board of Directors Expansion
On May 12, 2018, the Board expanded its size from ten to eleven members. Colleen F. Reitan was elected to fill the newly created vacancy, effective June 1, 2018. She will serve as a Class III director with a term expiring in 2019.
- Compensation: Annual cash fee of $50,000.
- Equity Grant: Stock option to purchase 18,000 shares vesting annually over three years.
- Future Awards: Eligible for annual stock option awards starting in 2019 (currently 9,000 shares per policy).
2018 Annual Meeting Results
The Annual Meeting was held on May 10, 2018. As of the record date (March 15, 2018), 100,171,389 shares were issued and outstanding. Key voting outcomes included:
- Director Re-elections (Class II): Stockholders re-elected Dennis A. Ausiello, M.D., John K. Clarke, Marsha H. Fanucci, and David E.I. Pyott. All received significant majority support, though John K. Clarke received approximately 7.3% of votes against.
- 2018 Stock Incentive Plan: Approved by stockholders. Approximately 27% of votes cast were against the plan (18,679,143 votes against vs. 68,819,642 for).
- Executive Compensation (Say-on-Pay): Approved in a non-binding advisory vote with overwhelming support (approx. 99% for).
- Auditor Ratification: PricewaterhouseCoopers LLP was ratified as the independent auditor for the fiscal year ending December 31, 2018.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on business outlook, or specific risk factors. The primary disclosure relates to the governance structure and shareholder approval of the stock incentive plan.
Investor Verification Checklist
- Verify the specific terms and vesting schedule of the 18,000-share option grant to Colleen F. Reitan.
- Review the full text of the 2018 Stock Incentive Plan to understand the implications of the shareholder approval, noting the significant minority vote against it.
- Confirm the total number of shares reserved under the newly approved Stock Incentive Plan (not detailed in this summary).
- Monitor the Company's upcoming 10-Q or 10-K filings for the financial metrics absent from this 8-K.